New β-Lactam–β-Lactamase Inhibitor Combinations-Reference-Cited by-同舟云学术

New β-Lactam–β-Lactamase Inhibitor Combinations

Published:2020-12-16 Issue:1 Volume:34 Page:
ISSN:0893-8512
Container-title:Clinical Microbiology Reviews
language:en
Short-container-title:Clin Microbiol Rev

Author:

Yahav Dafna¹²^ORCID,Giske Christian G.³,Grāmatniece Alise³⁴,Abodakpi Henrietta⁵,Tam Vincent H.⁵,Leibovici Leonard²⁶

Affiliation:

1. Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel

2. Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel

3. Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden

4. Pauls Stradins University Hospital, University of Latvia, Riga, Latvia

5. Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA

6. Medicine E, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel

Abstract

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa .

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health,General Immunology and Microbiology,Epidemiology

Link

https://journals.asm.org/doi/pdf/10.1128/CMR.00115-20

Reference329 articles.

1. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

2. 10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

3. New β-lactam antibiotics and β-lactamase inhibitors

4. FDA. 2014. Ceftolozane-tazobactam. Center for Drug Evaluation and Research. Approval package for application number 206829Orig1s000. FDA, Silver Spring, MD.

5. FDA. 2015. Ceftazidime-avibactam. Center for Drug Evaluation and Research. Approval package for application number 206494Orig1s000. AVYCAZ injection. FDA, Silver Spring, MD.

Cited by 323 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa;Diagnostic Microbiology and Infectious Disease;2024-12

2. A new type of Class C β-lactamases defined by PIB-1. A metal-dependent carbapenem-hydrolyzing β-lactamase, from Pseudomonas aeruginosa: Structural and functional analysis;International Journal of Biological Macromolecules;2024-10

3. Antibiotic adjuvants against multidrug-resistant Gram-negative bacteria: important component of future antimicrobial therapy;Microbiological Research;2024-10

4. Nanozymes and their biomolecular conjugates as next-generation antibacterial agents: A comprehensive review;International Journal of Biological Macromolecules;2024-10

5. ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime;Antimicrobial Agents and Chemotherapy;2024-09-04